



Press release

## **STRENGTHENING OF PHARMA SKILLS WITHIN THE CROSSJECT SUPERVISORY BOARD**

Dijon, 13 September 2018

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations,** announces the appointment of Dr Jean-François Loumeau to the Supervisory Board.

The Crossject Supervisory Board is pleased to welcome Dr Loumeau, a British doctor. His international experience in the pharmaceutical industry will be a valuable asset for Crossject. He will bring his expertise to the next stages of the company's development. Dr Loumeau has held numerous positions in the pharmaceutical industry, particularly in English-speaking markets. He has served in the commercial field for more than 20 years and the industrial sphere for more than 10 years. Dr Loumeau sits on the boards of directors of several pharmaceutical groups.

Dr Loumeau said: *"I am happy to be joining the Crossject Supervisory Board. This innovative company has all the assets to quickly become a world leader in the emergency field."*

Dr Loumeau replaces Philippe Schleicher, legal representative of SNPE. Mr Schleicher wished to withdraw from the Supervisory Board for reasons of availability. He said: *"We are delighted to be handing over to Dr Loumeau, whose experience will allow him to contribute significantly to Crossject's development. It is a compelling project, and one that SNPE has supported since its creation."* The Supervisory Board would like to thank Philippe Schleicher warmly for his contribution over the past year and a half.



**Next release:** 26 September 2018 (after trading): First-half 2018 results

## Contacts:

Crossject  
Patrick Alexandre  
[info@crossject.com](mailto:info@crossject.com)

Investor relations  
CM-CIC Market Solutions  
Catherine Couanau +33 (0)1 53 48 81 97  
[catherine.couanau@cmcic.fr](mailto:catherine.couanau@cmcic.fr)

Press relations  
Buzz & Compagnie  
Mélanie Voisard +33 (0)3 80 43 54 89  
[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)  
Audrey Lachat +33 (0)3 80 43 54 89  
[audrey.lachat@buzzetcompagnie.com](mailto:audrey.lachat@buzzetcompagnie.com)

## About CROSSJECT · [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, severe migraine, allergic shock, overdose and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and has notably received financing from Bpifrance.